LAUSR

BACKGROUND Web based patient-reported outcome measures (PROMs) could aid surgeons to remotely assess the need for examination and subsequent treatment of Dupuytren's disease (DD) patients. We studied whether the Unité Rhumatologique des affections de la Main (URAM) and the Michigan Hand Questionnaire (MHQ) could predict DD treatment. METHODS In this prospective cohort study, we compared MHQ and URAM scores of treated patients with untreated patients. For the treatment group, we selected a score closest to one year before treatment. For controls we randomly selected a score. Additionally, we tested the predictive value of a one-year change score between 15 months and 6 weeks before treatment. The primary outcome measure was DD treatment.The predictive value was determined using the Area Under the Curve (AUC). An AUC >0.70 was considered as good predictive ability, 0.70-0.50 as poor predictive ability and <0.50 as no predictive ability. RESULTS We included 141 patients for the MHQ analysis and 145 patients for the URAM analysis. The AUC of the MHQ and URAM scores measured one year before treatment were 0.80 (95% CI 0.71-0.88) and 0.75 (95% CI 0.68-0.82), respectively. The one-year change score resulted in an AUC of <0.60 for both questionnaires. CONCLUSIONS Our results show that both the MHQ and URAM score measured around one year before treatment can predict treatment for DD. If future studies show that telemonitoring of DD patients with PROMs is also cost-effective, web-based PROMs could optimise patient care and treatment effectiveness of DD.